GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » Cash, Cash Equivalents, Marketable Securities

Valeo Pharma (TSX:VPH) Cash, Cash Equivalents, Marketable Securities : C$6.89 Mil (As of Apr. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Valeo Pharma Cash, Cash Equivalents, Marketable Securities?

Valeo Pharma's quarterly cash, cash equivalents, marketable securities increased from Oct. 2023 (C$7.50 Mil) to Jan. 2024 (C$9.59 Mil) but then stayed the same from Jan. 2024 (C$9.59 Mil) to Apr. 2024 (C$6.89 Mil).

Valeo Pharma's annual cash, cash equivalents, marketable securities increased from Oct. 2021 (C$2.04 Mil) to Oct. 2022 (C$22.50 Mil) but then declined from Oct. 2022 (C$22.50 Mil) to Oct. 2023 (C$7.50 Mil).


Valeo Pharma Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Valeo Pharma's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valeo Pharma Cash, Cash Equivalents, Marketable Securities Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial 0.34 2.84 2.04 22.50 7.50

Valeo Pharma Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.12 9.78 7.50 9.59 6.89

Valeo Pharma Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Valeo Pharma  (TSX:VPH) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Valeo Pharma Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Valeo Pharma's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Valeo Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
Executives
Luc Mainville Senior Officer

Valeo Pharma Headlines

No Headlines